Enumeral Appoints Paul J. Sekhri to its Board of Directors

Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today it appointed Paul J. Sekhri to its Board of Directors. Mr. Sekhri is an accomplished industry executive, with more than 25 years of experience in life sciences strategy, corporate development and corporate finance, having served in senior leadership positions at several pharmaceutical companies, including Novartis, Teva and Sanofi. He is currently President and Chief Executive Officer of Lycera, and he also serves on its board of directors.

“Paul has significant experience in developing strategic relationships and corporate collaborations for biopharmaceutical companies through both management and board roles. We welcome his contributions to our Board and the guidance he provides our management team,” said Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer of Enumeral.

John J. Rydzewski, Executive Chairman of Enumeral, added, “Paul adds important biopharmaceutical industry experience to our team, and his successful track record of service as an independent director of public biotech companies will greatly benefit Enumeral in achieving our strategic and operational objectives on behalf of our shareholders.”

“I am delighted to join Enumeral’s board of directors and appreciate the opportunity to work with them in support of the company’s internal pipeline development and strategic partnering activities,” said Mr. Sekhri. “Enumeral is in a unique position to advance immunotherapy discovery and development, having assembled an exceptional management team and a platform to elucidate fundamental knowledge on how immunotherapies work in each patient.”

Prior to joining Lycera, Mr. Sekhri was Senior Vice President, Integrated Care at Sanofi, and before that, he served as Group Executive Vice President, Global Business Development and Chief Strategy Officer at Teva Pharmaceutical Industries. Prior to this, Mr. Sekhri was Operating Partner and Head, Biotech Operations Group at TPG Biotech, where he was responsible for a portfolio of more than 50 life science firms. Previously, Mr. Sekhri was founder, President and Chief Executive Officer of Cerimon Pharmaceuticals, and before Cerimon, he was President and Chief Business Officer of Ariad Pharmaceuticals. He also held senior positions at Novartis, including Senior Vice President and Head, Global Search and Evaluation and M&A. Mr. Sekhri is also a director of Veeva Systems and has served as a director on numerous private and public company boards, including KAI Pharmaceuticals, Intercept Pharmaceuticals, Macrogenics, PatientSafe Solutions and Tandem Diabetes, and as a board advisor to IMS Health. He serves on the Board of Trustees for the non-profit Cancer Research Institute and on the Industry Advisory Boards of the Michael J. Fox Foundation, the TB Alliance and the Tectonic Theatre Project. Mr. Sekhri received a B.S. from the University of Maryland and completed postgraduate studies in clinical anatomy and neuroscience at the University of Maryland, School of Medicine.

About Enumeral

Enumeral is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells. We believe we have a unique ability to extensively interrogate the human immune microenvironment for candidate selection and validation. We believe our unique capabilities enable us to measure drug effects in a patient-specific manner, providing the basis for developing best-in-class product candidates, based on a fundamental understanding of how immunotherapies work in each patient. We are building a pipeline of immunomodulators for the treatment of cancer and inflammatory diseases and leveraging the breadth of our technology through strategic collaborations. http://www.enumeral.com

Forward Looking Statements Disclosure

This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements reflect current beliefs of Enumeral Biomedical Holdings, Inc. (“Enumeral”) with respect to future events and involve known and unknown risks, uncertainties, and other factors affecting operations, market growth, services, products and licenses. No assurances can be given regarding the achievement of future results, and although Enumeral believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, actual results may differ from the assumptions underlying the statements that have been made regarding anticipated events. More detailed information about Enumeral and risk factors that may affect the realization of forward-looking statements, including forward-looking statements in this press release, is set forth in Enumeral’s filings with the Securities and Exchange Commission. Enumeral urges investors and security holders to read those documents free of charge at the Commission’s website at http://www.sec.gov. Forward-looking statements speak only as to the date they are made, and except for any obligation under the U.S. federal securities laws, Enumeral undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.